News | January 22, 2013

Treatment Chair Developed By Procure Improves Patient Comfort, Increases Efficiency of Care

Device allows patients to sit up during cancer treatments

An innovative modification of a treatment chair used with cancer patients allows those who have problems lying down during procedures to sit upright, providing greater comfort. The modified chair was developed to be used for proton therapy but can also be used in conventional radiation therapy, providing the chair can be attached to a robotic positioner.   

Engineers at ProCure Treatment Centers, Inc. (ProCure), which develops and operates a network of proton centers in the U.S., developed an intra-cranial chair to address the difficulty some patients have when they need to lie flat for treatment. The chair also gives proton centers the option of using less expensive beam delivery systems rather than large gantry systems, the industry standard for treating these cases, as it was designed with multiple rotation points that complement the limited beam angles offered by the inclined or fixed beam systems. ProCure also developed the inclined beam technology, which can be used to treat approximately 80 percent of tumors that normally require the use of a gantry, but in a space about half the size.
“Some patients, especially those with head and neck tumors, have difficulty swallowing while lying on a standard treatment table,” said Eugen Hug, M.D., ProCure medical director and chief medical officer. “Not only is this device helpful in greatly enhancing patient comfort but it improves patient flow by allowing us to use the inclined beam system for more people.” 
The intra-cranial chair is in use at ProCure’s Oklahoma and Illinois centers and is now commercially available to other proton centers, hospitals and radiation oncology practices.
 
“Our sole focus is providing exceptional patient care and we continue to do that by developing new innovations that place our patient’s comfort front and center,” said Niek Schreuder, senior vice president of medical physics and technology at ProCure. “Our engineers at the ProCure Training and Development Center strive to bring new and improved technology to cancer therapy, not only for our center but for all practices that are treating patients who could benefit.”
 
Proton therapy is an advanced form of radiation and an important alternative to standard X-ray radiation for many patients with cancer and for some noncancerous tumors. Proton therapy has been shown to be beneficial in the treatment of a broad range of tumor types including brain, central nervous system, gastrointestinal, head and neck, lung and prostate as well as sarcomas and many pediatric cancers. The precision of proton therapy makes it especially effective for treating children and adults with anatomically complex tumors such as base of skull and tumors along the spinal cord.
 
For more information: www.ProCure.com
 

Related Content

Eight Proton Therapy Centers Worldwide Adopt RayStation for Treatment Planning
News | Treatment Planning | July 21, 2017
RaySearch Laboratories reported that eight additional proton therapy centers worldwide have recently chosen RayStation...
IBA to Install Proton Therapy Facility at Inova Schar Cancer Institute
News | Proton Therapy | July 18, 2017
IBA (Ion Beam Applications S.A.) and Inova recently signed a contract for a two-room Proteus Plus proton therapy...
Proton International and Beaumont Health Open Michigan's First Proton Therapy Facility
News | Proton Therapy | July 17, 2017
Proton International (PI) and Beaumont Health recently opened the state’s first proton therapy center, offering the...
ASTRO Updates Insurance Coverage Recommendations for Proton Therapy
News | Proton Therapy | July 17, 2017
The American Society for Radiation Oncology (ASTRO) has issued an update to its recommendations for medical insurance...
Elekta’s MR-linac integrates an advanced linear accelerator and a 1.5T magnetic resonance imaging (MRI) system

Elekta’s MR-linac integrates an advanced linear accelerator and a 1.5T magnetic resonance imaging (MRI) system. Combined, these systems will allow for simultaneous radiation therapy delivery and high-field MR tumor monitoring.

Feature | Radiation Oncology | July 05, 2017 | By Jeff Zagoudis
Image-guided radiation therapy offers great potential to improve the efficiency of treating cancer patients by more...

Photo courtesy of RaySearch

Feature | Treatment Planning | July 05, 2017 | By Jeff Zagoudis
While radiation oncologists have a number of proven techniques at their disposal for treating patients, the reality is...
IBA and Philips Step Up Commercial Collaboration in Brazilian Proton Therapy Market
News | Radiation Therapy | July 03, 2017
IBA and Philips announced in mid-June they are stepping up their combined effort for proton therapy in Brazil.
Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017
In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may...
Versa

Image courtesy of Elekta

News | Radiation Therapy | June 13, 2017
Radiation therapy (RT) using high-energy particles, like X-rays or electron beams, is a common and critical component...
News | Radiation Oncology | June 12, 2017
The alliance will study the feasibility of using CRnR’s converging x-ray lens technology as an effective radiotherapy...
Overlay Init